|
|Section2= |Section3= }} Epalrestat is a noncompetitive and reversible aldose reductase inhibitor used for the treatment of diabetic neuropathy, which is one of the most common long-term complications in patients with diabetes mellitus. It is well tolerated, with the most commonly reported adverse affects being gastrointestinal issues such as nausea and vomiting, as well as increases in certain liver enzymes. Chemically, epalrestat is unusual in that it is a drug that contains a rhodanine group. == Brand name == # Eparel 50(Microlabs Ltd),India # Aldonil (Zydus Medica), India # Alrista (Macleods),India # LISTAP-50'' (VIVID BIOTEK),India # EPALRICA-M'' (ORDAIN GLOBAL),INDIA # EPLISTAT 150 SR (schem),India # EPIMETH (Zaiva Lifesciences),India # Aldorin in Bangladesh # Letostat-SR''(AMOR Pharmaceuticals)India 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「epalrestat」の詳細全文を読む スポンサード リンク
|